版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
·研寫TheIntroduction?–Whatdidyou·研寫TheIntroduction?–Whatdidyou?Whatdidyou科研論文四部分,主要內(nèi)容有哪些?Whatdoyourfindings ?–Whydidyoudothe–Whatwasyourhypothesisor本課內(nèi)·本課內(nèi)·研寫????Introduction寫作順·研寫inIntroduction寫作順·研寫in·研寫·研寫Settingthe(策略性)長(zhǎng)度——10-15%oftheIntroduction包括的內(nèi)·研Introduction包括的內(nèi)·研寫GapinHypothesis/purposestatementStrategyfortestinghypothesisorachievingpurpose123,·研·研寫·研寫Gapin·研寫Gapin?從已知到未知強(qiáng)調(diào)填補(bǔ)這個(gè)gap的重要“However,wedonotknowwhateffectthistreatmentwillhaveonpatientswithstageIV“Whetherthesefindingswilltranslatetotheclinicalsettingisnotknown.”“Paststudiesofthisissuehaveresultedinconflictingfindings.”“Sofar,onlyqualitativefindingshavebeen“However,littleisknownaboutthelong-termimpactoncellfunctionsofraisedlevelsofAlthoughseveralstudieshaveassociatedQRSexpressionwithcolorectaladenocarcinoma,thedirecteffectsofQRSonestablishedcolorectalcancershavenotbeendetermined.AnunderstandingofhowQRScontributestotumorigenicityincolorectalcancercellsmayenableitsuseasaprognosticfactororeventherapeutic???????·研寫·研寫出現(xiàn)的三地方——introduction,abstract,In“WehypothesizedthattheRb-E2F1pathwayisoneofthecriticaltumor-suppressor/oncogenepathwaysinvolvedinregulatingtelomeraseexpressionandactivityinglioblastoma.”In“WefoundthattheRb-E2Fpathwayisinvolvedinregulatingtelomeraseexpressionandactivityincancerandnormalcells...”實(shí)驗(yàn)方實(shí)驗(yàn)方·研寫“WeidentifiedthesequencesdownstreamfromtheTATAboxinbasalHypothesisInthisstudy,wetestedthehypothesisthatvariationsinothermembersoffibulingenefamilyareinvolvedinthepathogenesisofmaculardegenerationbyexaminingthecodingsequencesofthegenesforfibulin1,2,4,5,and6inmorethan400patientswithage-relatedmaculardegeneration.·研寫·研寫Totestthishypothesis,weexaminedB-celllymphomasthatcarriedspecificchromosomaltranslocations.Ineachcase,avaryingproportionofthemicrovascularendothelialcellsofthelymphomaexhibitedthelymphoma-specificgeneticaberration,suggestingacloserelationshipbetweenthetwotypesofcells.·研寫Known·研寫Known(generalto1Includeonlyenoughbackgroundtomakethereasonforthestudy23Organizetheinformationlikeafunnel,fromgeneralto·研寫Gap·研寫Gapin??Untilnow,ithasnotbeenpossibletoHowever,wedonotknowwhateffectthistreatmentwillhaveon...Therehasbeensomedisagreement,however,inthefindingswiththismodel...Sofar,onlyqualitativefindingshavebeenBecauseoftherarityofthiscancer,ithasbeendifficulttodeterminesurvivalrateswithstatisticalcertainty...???·研寫·研寫???Thepurposeofourstudywastodetermine...Wehypothesizedthat...Ourhypothesiswas·研寫·研寫??WetestedourhypothesisbyTodothis,weused...andanalyzed...inaninsitu·研寫·研寫??Overall,ourfindingsthat…Inthisstudy,wefound·研寫TheriskofcancercanbesignificantlyincreasedbydisruptionofgenomicintegrityresultedfromdysfunctionalDNAdamageresponsesignalingand/oraberrantactivityofthekeycomponentsintheDNArepairpathways.TheDNArepairmachineriesworkconstantlytoremovenumerousDNAlesionscausedbychemotherapeuticagentssuchascisplatin,whichcontributestodrugresistanceinmanycancers.Asresistancetostandardcisplatin-basedchemotherapybecomesafrequentphenomenon,cancertreatmenttargetingimportantcomponentsintheDNArepairpathwaysemergestobeanimminentandcompellingtask.RDM1(RAD52motif1,orRDmotif)isinvolvedincellularresponsetocisplatin,andshowssimilaritiestoRAD52,akeyregulatorinDNArecombinationandrepair,wheretheRDmotifofRDM1functionallyresemblestheN-terminalregionofRAD52[1-3].Importantly,RDM1–/–cellsexhibitedincreasedsensitivitytocisplatin[4].Moreinterestingly,ourinitialcomprehensivebioinformaticsexplorationinmultipleOncomineexpressiondatasetshasalsoidentifiedRDM1asoneofthesignificantlyup-regulatedproteinsinhumanlungadenocarcinoma.Despitethesediscoveries,however,todate,littleisknownregardingtheroleofRDM1inhumancancer.GiventhepotentialroleofRDM1intheDNArepairpathwaysthatconstituteanimportantaspectofcancerinitiationandprogression,weproposethatRDM1maydisplayoncogenicpropertiesanddrivetumorigenesis.·研寫Lungcancerisaleadingcauseofcancerdeaths,andremainsoneoftherefractorycancertypes.Adenocarcinomaaccountsfor40%ofalllungcancers.Thefive-yearsurvivalrateoflungcanceristhelowestamongthemajorcancers,includingcolon,breast,andprostatecancers[5].Evenwithmajorclinicalinterventions,suchassurgery,radiationtherapy,chemotherapy,targetedcancertherapy,andimmunotherapy,thesurvivalratehasnotbeenimprovedsignificantly,andlingersatonly15%withinfiveyearsoftreatment[6].TheclinicalstagingoflungcancersfollowstheTNMclassificationsystem,wherethedeterminingfactorsinclude:thesizeoftheprimarytumor(T),theeffectsontheregionallymphnodes(N),andthedistantmetastaticstatus(M).Recentyearshavewitnessedsomesuccessintargetedtherapiesforparticularmutationsinlungadenocarcinoma,suchasthoseinEGFRandALK,andthesestrategieshavebeenapprovedforuseasfirst-linetreatmentinadenocarcinoma[7-9].Conceptually,investigationofthemutationallandscapeinlungadenocarcinomawillhelpidentifynewtargetswhichcanbeenlistedtothegrowingbiomarkerpanelthatmayassistwiththediagnosis.Asaresult,itisimperativetouncovermorenovelmolecules,whichwillbebeneficialtothetreatmentanddiagnosisoflungadenocarcinoma.·研寫Inthisstudy,wefoundthatRDM1isup-regulatedinclinicallungadenocarcinomasamplesasrevealedbyIHCstaining.Significantly,up-regulationofRDM1iscorrelatedwithpoorclinicalcharacteristicsandriskfac
溫馨提示
- 1. 本站所有資源如無(wú)特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 2024年國(guó)際私人民間貿(mào)易協(xié)議樣式
- 2024年期企業(yè)互保反擔(dān)保協(xié)議樣本
- 2024年企業(yè)勞動(dòng)協(xié)議范本要點(diǎn)
- 2024廣告影片拍攝場(chǎng)地使用協(xié)議
- DB11∕T 1570-2018 甜瓜設(shè)施栽培技術(shù)規(guī)程
- 2024年鋼材供應(yīng)協(xié)議鋼筋條款詳本
- 2024年適用場(chǎng)地租賃協(xié)議模板
- 不銹鋼欄桿建設(shè)施工服務(wù)協(xié)議2024
- 2024年定制銷售受托管理協(xié)議
- 2024年度特定物資委托采購(gòu)合作協(xié)議
- 2024年全國(guó)教育大會(huì)精神全文課件
- 廣東省珠海市2023-2024學(xué)年六年級(jí)上學(xué)期數(shù)學(xué)期中試卷(含答案)
- 企業(yè)公司工會(huì)管理制度
- 肺結(jié)節(jié)診治中國(guó)專家共識(shí)(2024年版)解讀
- 2024年人教版八年級(jí)道德與法治上冊(cè)期中考試卷(附答案)
- (高清版)JTGT 3365-02-2020 公路涵洞設(shè)計(jì)規(guī)范
- 氣壓止血帶在四肢手術(shù)中應(yīng)用的專家共識(shí)(2021版)
- 食堂工作人員安全技術(shù)交底
- 多重中介模型及其應(yīng)用
- 可分離變量的微分方程(8)課件
- 蘇教版小學(xué)一年級(jí)數(shù)學(xué)上冊(cè)期末試卷
評(píng)論
0/150
提交評(píng)論